CIDRAP newsletters options
The 38 businesses operated or facilitated access to 60 clinics, almost all in the United States and Mexico.
Survey respondents gave the terms "antimicrobial resistance' and 'AMR' low scores for risk association and memorability.
The study suggests the seasonal flu vaccine could be a tool to help address rising antibiotic resistance.
The estimated percentage of JN.1 viruses is very small—about 0.1%.
Testing during inspection revealed positive microbiological samples in the facility's key production areas.
The analysis included 806 patients who were infected with the wild-type strain, Alpha, Delta, or Omicron strain.
The researchers estimated 1 in 30 hospitalizations among newly infected adults aged 80 years and older.
In a variant proportion update, the CDC said HV.1 has nudged ahead of EG.5.
Relative to uninfected adults, those with COVID-19 had a 37% higher rate of severe physical symptoms.
Thirty-day death rates were 8% in the Omicron group, 3% in flu patients, and 6% in the RSV group.
Formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2.
In influenza news, US flu cases appear to be rising, and officials have confirmed more avian flu outbreaks in US poultry.
Simvastatin had been shown to reduce pulmonary and systemic inflammation in mouse and human models of lung injury.
A second study showed that COVID-19 survivors had higher rates of most studied symptoms than controls, with the greatest risks for shortness of breath, fatigue, memory loss, and headache.
The FDA last week approved Pfizer's new vaccine, called Penbraya, which covers five serogroups.
With the exact source still murky and investigations still under way, officials expect more cases.
The roadmap aims to help countries in the region identify, prioritize, implement, and monitor high-impact interventions to address AMR across the One Health spectrum.
While antibiotic use at three Chicago hospitals increased in COVID-19 patients at the outset of the pandemic, it declined among non–COVID patients.
Relative vaccine effectiveness was an additional 50% against critical illness.
Today's recommendation also sets the stage for transition to the commercial market in the months ahead.
